NASDAQ:TNXP - Tonix Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.94 +0.08 (+4.30 %) (As of 02/18/2019 02:23 PM ET)Previous Close$1.86Today's Range$1.86 - $1.9852-Week Range$1.70 - $51.10Volume292,552 shsAverage Volume383,983 shsMarket Capitalization$2.97 millionP/E Ratio-0.07Dividend YieldN/ABeta1.84 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a pre-investigational new drug (pre-IND) application stage, designed as a daytime administration for the treatment of PTSD; and TNX-801, a live synthetic version of horsepox virus at the pre-IND application stage. Its product pipeline also includes TNX-301, a potential treatment for AUD; and TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York. Receive TNXP News and Ratings via Email Sign-up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TNXP Previous Symbol CUSIPN/A Webwww.tonixpharma.com Phone212-980-9155Debt Debt-to-Equity RatioN/A Current Ratio6.79 Quick Ratio6.79Price-To-Earnings Trailing P/E Ratio-0.07 Forward P/E Ratio-0.08 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$31.55 per share Price / Book0.06Profitability EPS (Most Recent Fiscal Year)($29.00) Net Income$-21,120,000.00 Net MarginsN/A Return on Equity-130.30% Return on Assets-115.43%Miscellaneous Employees14 Outstanding Shares1,529,000Market Cap$2.97 million OptionableOptionable Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions What is Tonix Pharmaceuticals' stock symbol? Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP." When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work? Tonix Pharmaceuticals's stock reverse split on Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split. How were Tonix Pharmaceuticals' earnings last quarter? Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) issued its quarterly earnings results on Friday, November, 9th. The company reported ($5.70) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($6.10) by $0.40. View Tonix Pharmaceuticals' Earnings History. When is Tonix Pharmaceuticals' next earnings date? Tonix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Tonix Pharmaceuticals. What price target have analysts set for TNXP? 3 analysts have issued 1-year target prices for Tonix Pharmaceuticals' shares. Their predictions range from $10.00 to $80.00. On average, they anticipate Tonix Pharmaceuticals' share price to reach $45.00 in the next year. This suggests a possible upside of 2,219.6% from the stock's current price. View Analyst Price Targets for Tonix Pharmaceuticals. What is the consensus analysts' recommendation for Tonix Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tonix Pharmaceuticals. Has Tonix Pharmaceuticals been receiving favorable news coverage? Headlines about TNXP stock have trended somewhat positive this week, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Tonix Pharmaceuticals earned a daily sentiment score of 1.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. Who are some of Tonix Pharmaceuticals' key competitors? Some companies that are related to Tonix Pharmaceuticals include ERBA Diagnostics (ERBA), Endonovo Therapeutics (ENDV), Sunwin Stevia International (SUWN), MYOS (MYOS), International Stem Cell (ISCO), DelMar Pharmaceuticals (DMPI), Cyclacel Pharmaceuticals (CYCC), NeuroVive Pharmaceutical (NEVPF), Vital Therapies (VTL), MusclePharm (MSLP), Aytu Bioscience (AYTU), Dare Bioscience (DARE), Cellectar Biosciences (CLRB), Regulus Therapeutics (RGLS) and Peak Pharmaceuticals (PKPH). Who are Tonix Pharmaceuticals' key executives? Tonix Pharmaceuticals' management team includes the folowing people: Dr. Seth Lederman, Co-Founder, Pres, CEO & Chairman (Age 61)Mr. Bradley Saenger, CFO & Treasurer (Age 45)Dr. Gregory M. Sullivan, Chief Medical Officer & Sec. (Age 53)Mrs. Jessica Edgar Morris, Chief Operating OfficerDr. Ronald R. Notvest Ph.D., MBA, Exec. VP of Commercial Planning and Devel. Who are Tonix Pharmaceuticals' major shareholders? Tonix Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (1.13%), Geode Capital Management LLC (1.07%), CVI Holdings LLC (1.07%) and Citigroup Inc. (1.02%). Company insiders that own Tonix Pharmaceuticals stock include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Institutional Ownership Trends for Tonix Pharmaceuticals. Which major investors are selling Tonix Pharmaceuticals stock? TNXP stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC. View Insider Buying and Selling for Tonix Pharmaceuticals. Which major investors are buying Tonix Pharmaceuticals stock? TNXP stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, CVI Holdings LLC and Citigroup Inc.. Company insiders that have bought Tonix Pharmaceuticals stock in the last two years include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Insider Buying and Selling for Tonix Pharmaceuticals. How do I buy shares of Tonix Pharmaceuticals? Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Tonix Pharmaceuticals' stock price today? One share of TNXP stock can currently be purchased for approximately $1.94. How big of a company is Tonix Pharmaceuticals? Tonix Pharmaceuticals has a market capitalization of $2.97 million. The company earns $-21,120,000.00 in net income (profit) each year or ($29.00) on an earnings per share basis. Tonix Pharmaceuticals employs 14 workers across the globe. What is Tonix Pharmaceuticals' official website? The official website for Tonix Pharmaceuticals is http://www.tonixpharma.com. How can I contact Tonix Pharmaceuticals? Tonix Pharmaceuticals' mailing address is 509 MADISON AVE SUITE 306, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected] MarketBeat Community Rating for Tonix Pharmaceuticals (NASDAQ TNXP)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 232 (Vote Outperform)Underperform Votes: 156 (Vote Underperform)Total Votes: 388MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals and other stocks. Vote "Outperform" if you believe TNXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNXP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2019 by MarketBeat.com StaffFeatured Article: How can you know how many shares are floating?